Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial.

BMC Cancer
Mathieu SpaasPiet Ost

Abstract

While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to respond. Preclinical data suggest that stereotactic body radiotherapy (SBRT) could work synergistically with CPIs by acting as an in situ cancer vaccine, thus potentially increasing response rates and prolonging disease control. Though SBRT administered concurrently with CPIs has been shown to be safe, evidence of its efficacy from large randomized trials is still lacking. The aim of this multicenter randomized phase II trial is to assess whether SBRT administered concurrently with CPIs could prolong progression-free survival as compared to standard of care in patients with advanced solid tumors. Ninety-eight patients with locally advanced or metastatic disease will be randomized in a 1:1 fashion to receive CPI treatment combined with SBRT (Arm A) or CPI monotherapy (Arm B). Randomization will be stratified according to tumor histology (melanoma, renal, urothelial, head and neck squamous cell or non-small cell lung carcinoma) and disease burden (≤ or > 3 cancer lesions). The recommended SBRT dose is 24Gy in 3 fractions, which...Continue Reading

References

Jul 4, 2009·The Lancet Oncology·Silvia C Formenti, Sandra Demaria
Oct 1, 2010·Medical Physics·Stanley H BenedictFang-Fang Yin
Mar 9, 2012·The New England Journal of Medicine·Michael A PostowJedd D Wolchok
May 9, 2012·International Journal of Radiation Oncology, Biology, Physics·Emily F StamellIsaac Brownell
Jun 8, 2012·Science Translational Medicine·Steven K SeungWalter J Urba
Jul 9, 2013·Trends in Molecular Medicine·Marco DuranteKathryn D Held
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Mar 11, 2015·Nature·Christina Twyman-Saint VictorAndy J Minn
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jul 8, 2015·Vaccine·Claire Vanpouille-BoxSandra Demaria
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Nov 20, 2015·Current Problems in Cancer·Yazan AbuodehSungjune Kim
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Sep 30, 2016·International Journal of Radiation Oncology, Biology, Physics·Susan M HinikerSusan J Knox
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Mar 9, 2017·The Lancet Oncology·Lesley SeymourUNKNOWN RECIST working group
Jun 10, 2017·Nature Communications·Claire Vanpouille-BoxSandra Demaria
Jul 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James LarkinJeffrey Weber
Jul 16, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nadine Van RoyKatleen De Preter
Feb 28, 2018·International Journal of Radiation Oncology, Biology, Physics·Nora SundahlPiet Ost
Apr 6, 2019·International Journal of Radiation Oncology, Biology, Physics·Nora SundahlPiet Ost

❮ Previous
Next ❯

Software Mentioned

RECIST
R
SPSS
REDCap ( Research Electronic Data Capture )
iRECIST

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.